Gastro Medical News about Gastroduodenal Damage

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Proton Pump Inhibitors for Gastroduodenal Damage Related to Nonsteroidal Anti-inflammatory Drugs or Aspirin: Twelve Important Questions for Clinical Practice
Clinical Gastroenterology and Hepatology , 07/10/09

Arora G et al. - Nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin are among the most commonly used medications worldwide. Their use is associated with significant gastroduodenal adverse effects, including dyspepsia, bleeding, ulcer formation, and perforation. Given their long-term use by millions of patients, there is a substantial impact at the population level of these complications.

<< Previous
Worse recent efficacy of antiviral therapy in liver transplant...

Next >>
Characteristics of Patients With Cirrhosis Who Are Discharged...

Gastroduodenal toxicity of low-dose acetylsalicylic acid: a comparison with non-steroidal anti-inflammatory drugs
Current Medical Research and Opinion, 10/01/09 Relevance Score: 65%

DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells
BMC Cancer, 10/15/09 Relevance Score: 46%

Oxidative DNA damage in chronic renal failure patients
Nephrology Dialysis Transplantation, 11/05/09 Relevance Score: 45%

RoACTEMRA filed in Europe for the Inhibition of Joint Damage and Improvement in Physical Function in Rheumatoid Arthritis
Chugai Pharmaceutical Co., 10/16/09 Relevance Score: 45%

RoACTEMRA filed in Europe for the Inhibition of Joint Damage and Improvement in Physical Function in Rheumatoid Arthritis
Chugai Pharmaceutical Co., 10/14/09 Relevance Score: 45%